Tandem Diabetes Care (NASDAQ:TNDM) Stock Rating Upgraded by Wall Street Zen

Tandem Diabetes Care (NASDAQ:TNDM) was upgraded by equities research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued to investors on Friday.

A number of other brokerages have also recently commented on TNDM. Citigroup upped their price target on Tandem Diabetes Care from $20.00 to $24.00 and gave the stock a “neutral” rating in a research report on Thursday, May 22nd. Mizuho assumed coverage on Tandem Diabetes Care in a research note on Thursday, April 10th. They set a “neutral” rating and a $20.00 target price on the stock. Morgan Stanley downgraded Tandem Diabetes Care from an “overweight” rating to an “equal weight” rating and decreased their target price for the company from $45.00 to $22.00 in a research note on Wednesday, March 5th. Barclays decreased their target price on Tandem Diabetes Care from $60.00 to $53.00 and set an “overweight” rating on the stock in a research note on Friday, February 28th. Finally, Stifel Nicolaus reduced their price objective on Tandem Diabetes Care from $60.00 to $31.00 and set a “buy” rating on the stock in a research note on Thursday, May 1st. Nine analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Tandem Diabetes Care presently has a consensus rating of “Hold” and a consensus price target of $35.86.

Tandem Diabetes Care Trading Up 0.6%

Tandem Diabetes Care stock opened at $20.78 on Friday. The company has a current ratio of 2.90, a quick ratio of 2.32 and a debt-to-equity ratio of 1.29. The business’s fifty day simple moving average is $19.55 and its two-hundred day simple moving average is $26.83. Tandem Diabetes Care has a 12 month low of $15.75 and a 12 month high of $49.71. The company has a market capitalization of $1.38 billion, a price-to-earnings ratio of -10.77 and a beta of 1.52.

Tandem Diabetes Care (NASDAQ:TNDM) last announced its quarterly earnings results on Wednesday, April 30th. The medical device company reported ($0.67) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.07). The business had revenue of $234.42 million for the quarter, compared to the consensus estimate of $220.19 million. Tandem Diabetes Care had a negative net margin of 14.84% and a negative return on equity of 44.19%. The company’s revenue for the quarter was up 22.3% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.65) earnings per share. As a group, equities analysts predict that Tandem Diabetes Care will post -1.68 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Tandem Diabetes Care

Large investors have recently modified their holdings of the stock. AlphaQuest LLC increased its position in shares of Tandem Diabetes Care by 138.7% during the 4th quarter. AlphaQuest LLC now owns 931 shares of the medical device company’s stock valued at $34,000 after purchasing an additional 541 shares during the last quarter. Jones Financial Companies Lllp increased its position in shares of Tandem Diabetes Care by 195.8% during the 4th quarter. Jones Financial Companies Lllp now owns 1,130 shares of the medical device company’s stock valued at $41,000 after purchasing an additional 748 shares during the last quarter. Assetmark Inc. increased its position in shares of Tandem Diabetes Care by 77.5% during the 4th quarter. Assetmark Inc. now owns 1,225 shares of the medical device company’s stock valued at $44,000 after purchasing an additional 535 shares during the last quarter. Smartleaf Asset Management LLC increased its position in shares of Tandem Diabetes Care by 163.4% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,775 shares of the medical device company’s stock valued at $65,000 after purchasing an additional 1,101 shares during the last quarter. Finally, NBC Securities Inc. bought a new position in shares of Tandem Diabetes Care during the 1st quarter valued at approximately $37,000.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.